AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
StockNews.AI · 2 hours
AI Summary
AbbVie reported positive Phase 3 EPCORE-4 topline results for epcoritamab plus lenalidomide in relapsed/refractory DLBCL, showing significantly improved PFS versus R-GemOx (US HR 0.40; outside US 0.44; p<0.0001). Safety aligned with known profiles. AbbVie and Genmab will pursue regulatory discussions, with data to be presented at future meetings. Potentially expands epcoritamab's label and collaboration-driven growth.
Sentiment Rationale
Positive Phase 3 topline data for a high-profile oncology asset can prompt a near-term re-rating, especially with a clear regulatory path ahead and potential label expansion via collaboration.
Trading Thesis
Phase 3 topline data support near-term ABBV upside on regulatory momentum.
Market-Moving
- ABBV stock could react to topline results and regulatory updates.
- Potential upside from expanded epcoritamab indication and global filings.
- Genmab collaboration reduces execution risk and could boost upside.
- Volatility ahead as data are presented at future meetings.
Key Facts
- Phase 3 EPCORE-4: epcoritamab + lenalidomide improves PFS. HR US 0.40; global 0.44.
- Safety profile aligns with known data; no new safety signals.
- Regulators to discuss next steps; data to be presented at future meetings.
- AbbVie-Genmab collaboration supports broader epcoritamab commercialization.
- Topline: June 29, 2026.
Companies Mentioned
- AbbVie (ABBV): Lead sponsor; topline DLBCL data bolster oncology pipeline and regulatory momentum.
- Genmab A/S (GMAB): Co-developer; potential regulatory and commercialization leverage from EPCORE results.
Industry News
Industry News: reflects a corporate- and science-driven update on ABBV's oncology collaboration with Genmab, with potential near-term catalysts from regulatory discussions and data presentations.